Table of Contents

company-logo

Genor Biopharma Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company's principal drug candidates include GB242, an infliximab (Remicade) biosimilar for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, adult and pediatric crohn's disease, and fistulising crohn's disease; GB491 (lerociclib), an oral CDK4/6 inhibitor for treating hormone receptor-positive (HR+)/HER2- breast cancer and is under Phase III clinical trials; and GB492, a stimulator of interferon genes (STING) agonist expected to exert synergistic effects in combination with GB226 for solid tumors and is under Phase 1/2 clinical trial. Further, it develops GB221, a herceptin (trastuzumab)-mimic HER2 monoclonal antibody (mAb) drug candidate; geptanolimab (GB226), a novel PD-1 mAb drug candidate; GB223, a receptor activator of nuclear factor-B Ligand (RANKL) mAb drug candidate, which is under Phase I clinical trial; and GB261 to treat B-cell non-Hodgkin Lymphoma and is under Phase I Clinical trials. In addition, the company's product candidates under clinical trials include GB262, GB264, GB265, and GB 266 for the treatment of cancer. Genor Biopharma Holdings Limited was formerly known as JHBP (CY) Holdings Limited and changed its name to Genor Biopharma Holdings Limited in June 2021. The company was founded in 2007 and is headquartered in Shanghai, China.

Genor Biopharma Dividend Announcement

• Genor Biopharma does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Genor Biopharma dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Genor Biopharma Dividend History

Genor Biopharma Dividend Yield

Genor Biopharma current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Genor Biopharma stock? Use our calculator to estimate your expected dividend yield:

Genor Biopharma Financial Ratios

P/E ratio-1.65
PEG ratio-0.04
P/B ratio0.82
ROE-46.69%
Payout ratio0.00%
Current ratio5.76
Quick ratio5.73
Cash Ratio5.41

Genor Biopharma Dividend FAQ

Does Genor Biopharma stock pay dividends?
Genor Biopharma does not currently pay dividends to its shareholders.
Has Genor Biopharma ever paid a dividend?
No, Genor Biopharma has no a history of paying dividends to its shareholders. Genor Biopharma is not known for its dividend payments.
Why doesn't Genor Biopharma pay dividends?
There are several potential reasons why Genor Biopharma would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Genor Biopharma ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Genor Biopharma has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Genor Biopharma a dividend aristocrat?
Genor Biopharma is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Genor Biopharma a dividend king?
Genor Biopharma is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Genor Biopharma a dividend stock?
No, Genor Biopharma is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Genor Biopharma stocks?
To buy Genor Biopharma you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Genor Biopharma stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.